IN2014DN09240A - - Google Patents

Info

Publication number
IN2014DN09240A
IN2014DN09240A IN9240DEN2014A IN2014DN09240A IN 2014DN09240 A IN2014DN09240 A IN 2014DN09240A IN 9240DEN2014 A IN9240DEN2014 A IN 9240DEN2014A IN 2014DN09240 A IN2014DN09240 A IN 2014DN09240A
Authority
IN
India
Prior art keywords
combination
treatment
11beta
medicament
human
Prior art date
Application number
Other languages
English (en)
Inventor
Germo Hans Gericke
Herbert Anton Schmid
Lutomirsky Mario Roberto Maldonado
Li Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN09240A publication Critical patent/IN2014DN09240A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN9240DEN2014 2012-04-12 2013-04-10 IN2014DN09240A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623117P 2012-04-12 2012-04-12
PCT/EP2013/057515 WO2013153129A1 (fr) 2012-04-12 2013-04-10 Combinaison d'analogues de la somatostatine et d'inhibiteurs de la 11-bêta-hydroxylase

Publications (1)

Publication Number Publication Date
IN2014DN09240A true IN2014DN09240A (fr) 2015-07-10

Family

ID=48289057

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9240DEN2014 IN2014DN09240A (fr) 2012-04-12 2013-04-10

Country Status (13)

Country Link
US (1) US9333234B2 (fr)
EP (1) EP2836228B1 (fr)
JP (1) JP6383352B2 (fr)
KR (1) KR102136214B1 (fr)
CN (1) CN104321074B (fr)
AU (1) AU2013246908B2 (fr)
BR (1) BR112014025058B1 (fr)
CA (1) CA2869442C (fr)
ES (1) ES2980806T3 (fr)
IN (1) IN2014DN09240A (fr)
MX (1) MX362533B (fr)
RU (1) RU2663455C2 (fr)
WO (1) WO2013153129A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088188A1 (fr) * 2010-01-14 2011-07-21 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
PT3166596T (pt) * 2014-07-07 2018-10-19 Novartis Ag Formas farmacêuticas
WO2016048984A1 (fr) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Méthodes et compositions pour le traitement du syndrome de cushing basées sur le 2s,4r kétoconazole
WO2017127448A1 (fr) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Diagnostic différentiel du syndrome de cushing ectopique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509348A (en) * 1998-07-30 2004-02-27 Sod Conseils Rech Applic Use of a somatostatin analogue Lanreotide
MXPA03009048A (es) * 2001-04-09 2004-02-12 Univ Tulane Agonistas de la somatostatina.
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
JP5575913B2 (ja) * 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
WO2011088188A1 (fr) * 2010-01-14 2011-07-21 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
WO2013131879A1 (fr) * 2012-03-07 2013-09-12 Novartis Ag Nouvelle application pour la pasireotide

Also Published As

Publication number Publication date
AU2013246908B2 (en) 2016-06-30
WO2013153129A1 (fr) 2013-10-17
MX362533B (es) 2019-01-23
CA2869442C (fr) 2020-09-08
EP2836228B1 (fr) 2024-03-20
JP2015512923A (ja) 2015-04-30
MX2014012321A (es) 2015-09-24
KR102136214B1 (ko) 2020-07-22
RU2663455C2 (ru) 2018-08-06
JP6383352B2 (ja) 2018-08-29
US9333234B2 (en) 2016-05-10
RU2014145351A (ru) 2016-06-10
US20150087588A1 (en) 2015-03-26
CN104321074A (zh) 2015-01-28
EP2836228A1 (fr) 2015-02-18
ES2980806T3 (es) 2024-10-03
KR20150004831A (ko) 2015-01-13
CN104321074B (zh) 2017-09-08
CA2869442A1 (fr) 2013-10-17
AU2013246908A1 (en) 2014-10-23
BR112014025058B1 (pt) 2022-07-12
BR112014025058A2 (fr) 2017-06-20

Similar Documents

Publication Publication Date Title
TN2015000278A1 (en) Autotaxin inhibitors
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MY188382A (en) Spirocyclic inhibitors of cathepsin c
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
IN2015DN00528A (fr)
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
IN2014DN09240A (fr)
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2020005310A (es) Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
WO2015200768A3 (fr) Traitements pharmacologiques de la maladie de menière
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
WO2015126151A3 (fr) Composition pour la cicatrisation de plaies comprenant de l'extrait de massa medicata fermentata
WO2014155268A3 (fr) Inhibiteurs de kinase tyrosine fgf-r et leur utilisation dans le traitement de maladies associées à un manque ou à une absence d'activité snf5
MY159675A (en) Clerodane derivatives for modulation of leukotriene receptor activity and related diseases
IN2013MU01239A (fr)
IN2013MU01240A (fr)
IN2013MU01242A (fr)